Competitive Dealmaking Market Shifts To Smaller M&A, Partnering

Acquisition Numbers Rise, Values Fall In Q1

Dollars spent on biopharma M&A so far in 2024 may not be as high as in 2023, but dealmakers say deal volume is robust with many factors influencing the overall value of transactions this year.

Multiple stock graphs and numerical data overlaid on a cityscape, representing the finance and economy — Deals are happening, but they are not as large as in 2023 • Source: Shutterstock

Business development executives on site at this year’s BIO International Convention in San Diego noted that while the total dollar value of deals announced so far in 2024 may not be as high as it was at mid-year in 2023, negotiations for new partnerships and M&A are keeping dealmakers busy.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Cash-Strapped Chinese Biotechs A Growing Draw For Western Pharma Partnering

17 Feb 2025

• By Alaric DeArment

Nauman Shah, head of business development for J&J Innovation, sat down at the BIO CEO & Investor Conference to talk about his trip to China and the state of the biotech scene there.

Sutro Works Toward A Better Ovarian Cancer ADC

04 Jul 2024

• By Mandy Jackson

Sutro Biopharma CEO Bill Newell spoke with Scrip about the company’s novel platform, its goal of improving folate receptor alpha-driven ovarian cancer and its business development strategy.

Amgen’s Ian Thompson On Payer Shifts, Obesity Opportunity And The Future Of Blockbusters

28 Jun 2024

• By Mandy Jackson

Scrip spoke with Amgen’s senior VP of US business operations about the impact of drug pricing and reimbursement pressures coming from government policy changes and commercial payers.